          |
|
Niall A. O’Donnell, Ph.D., Associate and Kauffman Fellow Niall O’Donnell joined RiverVest in 2006 as a Kauffman Fellow. Dr. O’Donnell has both drug discovery and drug development experience and a strong background in immunology and glycobiology. Prior to joining RiverVest, Dr. O’Donnell was an immunologist at Johnson & Johnson, Pharmaceutical Research and Development in San Diego. He was part of a successful cross-disciplinary team of chemists and biologists that drove small molecule anti-inflammatory drugs into clinical trials. Dr. O’Donnell co-authored the first paper validating the newly discovered histamine H4 receptor as a key regulator of asthma and immune pathologies. At RiverVest, Dr. O’Donnell focuses on biopharmaceutical and medical device investments and serves as a board observer at Excaliard Pharmaceuticals, a Fund II portfolio company. Dr. O’Donnell has a Ph.D. in Biochemistry from the University of Dundee, Scotland, and read Natural Sciences at Pembroke College, Oxford. He also received an M.B.A. from the Rady School of Management of the University of California, San Diego, where he was a member of the inaugural class. Niall A. O'Donnell, Ph.D. |
©2005 RiverVest Venture Management, LLC